İsmail DOĞAN, Umut KALYONCU, Levent KILIÇ, Ali AKDOĞAN, Ömer KARADAĞ, Sedat KİRAZ, Şaziye Şule Apraş BİLGEN, Ali İhsan ERTENLİ

Avascular necrosis less frequently found in systemic lupus erythematosus patients with the use of alternate day corticosteroid

Background/aim: Avascular necrosis AVN is the death of bone due to compromise of blood flow. The etiology of AVN is multifactorial; corticosteroid usage is the second most significant factor after trauma, and systemic lupus erythematosus SLE is the most common underlying disease. The objective of this study was to assess the factors of AVN in SLE patients. Materials and methods: The study included 127 patients with SLE who fulfilled 1997 American College of Rheumatology ACR revised criteria. Demographic data, age at SLE diagnosis, disease duration, disease activity, body mass index, clinical findings, antiphospholipid syndrome, steroid usage, dose and duration, comorbid diseases, and smoking history were recorded. Results: AVN was found in 11 of 127 8.7% SLE patients. Hyperlipidemia P

Keywords:

Avascular necrosis, alternate day steroid usage, systemic lupus erythematosus,

PDF

___

1. Fukushima W, Fujioka M, Kubo T, Tamakoshi A, Nagai M et al. Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clinical Orthophedics and Related Research 2010; 468: 2715-2724.
2. Dubois E, Cozen L. Avascular necrosis associated with lupus erythematosus. Journal of the American Medical Association 1960; 174: 966-971.
3. Joo YB, Sung YK, Shim JS, Kim JH, Lee EK et al. Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: A nationwide epidemiologic study. Rheumatology International 2015; 35: 879-886.
4. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Seminars in Arthritis and Rheumatism 2002; 32: 94-124.
5. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatology 1997; 40: 1725.
6. Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis & Rheumatology 1999; 42: 1354-1360.
7. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis & Rheumatology 1999; 42: 1309-1311.
8. Sekiya F, Yamaji K, Yang K, Tsuda H, Takasaki Y. Investigation of occurrence of osteonecrosis of the femoral head after increasing corticosteroids in patients with recurring systemic lupus erythematosus. Rheumatology International 2010; 30: 1587-1593.
9. Sagakuchi M, Tanaka T, Fukushima W, Kubo T, Hirota Y. Impact of oral corticosteroid use for idiopathic osteonecrosis of the femoral head: a nationwide multicenter case-control study in Japan. Journal of Orthopedic Science 2010; 15: 185- 191.
10. Gladman DD, Dhillon N, Su J, Urowitz MB. Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors. Lupus 2018; 27 (1): 76-81. doi: 10.1177/0961203317711012
11. Sayarlioglu M, Yuzbsioglu N, Inanc M, Kamali S, Cefle A et al. Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatology International 2012; 32: 177-182.
12. Heshin-Bekenstein M, Trupin L, Yelin E, von Scheven E, Yazdany J et al. Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. Seminars in Arthritis and Rheumatism 2019; 49 (2): 267-272. doi: 10.1016/j.semarthrit.2019.05.010
13. Faezi ST, Hoseinian AS, Paragomi P, Akbarian M, Esfahanian F et al. Non-corticosteroid risk factors of symptomatic avascular necrosis of bone in systemic lupus erythematosus: A retrospective case-control study. Modern Rheumatology 2015; 25 (4): 590-594. doi: 10.3109/14397595.2014.987366
14. Smith FE, Sweet DE, Brunner CM, Davis JS. Avascular necrosis in SLE. An apparent predilection for young patients. Annals of the Rheumatic Diseases 1976; 35: 227-232.
15. Cozen L, Wallace DJ. Avascular necrosis in systemic lupus erythematosus: clinical associations and a 47-year perspective. American Journal of Orthopedics 1998; 27: 352-354.
16. Wang GJ, Rawles JG, Hubbard SL, Stamp WG. Steroid-induced femoral head pressure changes and their response to lipidclearing agents. Clinical Orthophedics and Related Research 1983: 174; 298-302.
17. Kuroda T, Tanabe N, Wakamatsu A, Takai C, Sato H et al. High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus. Clinical Rheumatology 2015; 34 (12): 2071-2077. doi: 10.1007/s10067- 015-3075-y
18. Kerachian MA, Seguin C, Harvey EJ. Glucocorticoids in osteonecrosis of the femoral head: A new understanding of the mechanisms of action. Journal of Steroid Biochemistry & Molecular Biology 2009: 114; 121-128.
19. Zhang K, Zheng Y, Jia J, Ding J, Wu Z. Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis. Clinical Rheumatology 2018; 37 (1): 5-11. doi: 10.1007/s10067-017-3820-5
20. Houssiau FA, N’Zeusseu Toukap A, Depresseux G, Maldague BE, Malghem J et al. Magnetic resonance imaging-detected avascular osteonecrosis in systemic lupus erythematosus: lack of correlation with antiphospholipid antibodies. British Journal of Rheumatology 1998; 37: 448-453.
21. Mok CC, Lau CS, Wong RW. Risk factors for avascular bone necrosis in systemic lupus erythematosus. British Journal of Rheumatology 1998; 37: 895-900.
22. Migliaresi S, Picillo U, Ambrosone L, Di Palma G, Mallozzi M et al. Avascular necrosis in patients SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 1994; 3: 37-41.
23. Asherson RA, Liote F, Page B, Meyer O, Buchanan N et al. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. Journal of Rheumatology 1993; 20: 284-288.
24. Hisada R, Kato M, Ohnishi N, Sugawara E, Fujieda Y et al. Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis of the femoral head in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2019; 58 (4): 645-649. doi: 10.1093/rheumatology/key365
25. Zalavras C, Shah S, Birnbaum MJ, Frenkel B. Role of apoptosis in glucocorticoid-induced osteoporosis and osteonecrosis. Critical Reviews in Eukaryotic Gene Expression 2003; 13: 221- 235.
26. Powell C, Chang C, Naguwa SM, Cheema G, Gershwin ME. Steroid induced osteonecrosis: An analysis of steroid dosing risk. Autoimmunity Reviews 2010; 9: 721-743.
27. Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N et al. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. American Journal of Kidney Diseases 2003; 41: 1155-1162.
28. Yang L, Boyd K, Kaste SC. A Mouse model for glucocorticoidinduced osteonecrosis: effect of a steroid holiday. Journal of Orthopaedic Research 2009; 27: 169-175.
29. Mattano LA Jr, Devidas M, Nachman JB, Sather HN, Hunger SP et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncology 2012; 13 (9): 906-915.
30. Dumler F, Levin NW, Szego G, Vulpetti AT, Preuss LE. Longterm alternate day steroid therapy in renal transplantation. A controlled study. Transplantation 1982; 34: 78-82.